The Best ASX Biotech Stocks
to buy Now In
March 2024

Check out our Industry Experts’ report and
analysis on the best biotech stocks right now in ASX

The Best ASX Biotech Stocks
to buy Now In
March 2024

Check out our Industry Experts’ report and
analysis on the best biotech stocks right now in ASX

What are Biotech stocks?

Biotech companies are all about innovation and breakthroughs in healthcare. These companies are at the forefront of using living organisms and biological systems to revolutionize medicine and agriculture.

They're not just about creating new drugs; they're also involved in groundbreaking research in areas like genetic engineering. The biotech sector is where science meets the future, offering exciting possibilities in improving health and fighting diseases. This is a dynamic field where cutting-edge research can lead to life-changing advancements, making biotech stocks a fascinating area for investment.

Why Invest in Biotechnology Companies in Australia

Investing in biotech stocks is like backing the future of medicine. These companies are often on the cutting edge, developing groundbreaking treatments for a range of illnesses, sometimes even those that have eluded cure for years. When their research hits the mark, the financial rewards can be substantial.

What's more, the biotech sector marches to its own drum, often unaffected by the ups and downs of the economy. This makes it a smart choice for diversifying your investment portfolio, offering a unique blend of high growth potential.

Get the Latest Stock Market Insights for Free with
Stocks Down Under & Pitt Street Research

Join our newsletter and receive exclusive insights, market trends, investment tips, and updates delivered directly to your inbox. Don't miss out – subscribe today!

What to look for when investing in Australian Biotech Stocks

When considering biotech stocks, a thoughtful approach is essential. Start by examining the company's research pipeline. What kinds of drug candidates are they developing? Are these diverse and promising? The strength and experience of the management team are also crucial, especially their ability to handle complex clinical trials and regulatory hurdles.

Equally important is the company's financial stability. Biotech firms often require substantial funding for research and development, so robust financial health is a key indicator of their potential for success. Regulatory milestones are significant influencers of stock value and should be monitored closely. Also, assess the market demand for their products and the competitive landscape.

The Future Outlook of the ASX Biotechnology Sector

The Australian biotechnology sector is on the cusp of an exciting era. Known for hitting targets and making significant breakthroughs, this industry is set for a surge in growth. A key driver of this upswing is the expected pause in U.S. interest rate hikes, which traditionally boosts biotech investment.

Additionally, the sector is buzzing with mergers and acquisitions, as big pharma companies and life sciences industry are eager to snap up innovative biotech startups. This flurry of activity signals a vibrant future for the industry, filled with opportunities and advancements.

5 Best ASX Biotech Stocks to Buy Now in 2024


CSL Limited (ASX:CSL)

CSL Limited offers a solid investment opportunity, particularly highlighted by its expected growth phase and positive endorsements from notable brokers like Citi, UBS, and Goldman Sachs. This biotech leader is poised for significant earnings growth, driven by increased plasma collection and the potential approval of new products.


ResMed (ASX:RMD)

ResMed Inc. is shaping up to be an enticing investment pick. With a strong recovery from its yearly low, it's catching the eye of top analysts who foresee a bright future. They're betting on a robust 27% upside, driven by solid growth across its products. Despite some market jitters over new drugs, the experts are confident these concerns are overblown.



Telix Pharmaceuticals (ASX:TLX)

Telix Pharmaceuticals is an exciting investment choice in the biotech field, especially for its groundbreaking work in cancer treatments. With a remarkable 165% jump from its 2022 low point, the company has made a significant leap from a pre-revenue stage to earning revenue, thanks to the successful launch of Illucix, their prostate cancer imaging product.


Neuren Pharmaceuticals (ASX:NEU)

This company is making waves in the biotech sector, notably with its breakthrough Rett syndrome treatment, Daybue. This game-changer has not only brought substantial royalty income but also placed Neuren at the forefront of innovative medical solutions, increasing its market capitalization substiantially in the past year.


Avita Medical (ASX:AVH)

AVITA Medical is making waves in regenerative medicine, with its share price skyrocketing over 120% in 2023. The company’s recent quarterly report revealed a stellar 50% jump in revenue, signalling strong market traction. Analysts are lining up in support, with all giving a thumbs-up. The buzz is building for its upcoming yearly results..


5 Best ASX Biotech Stocks to Buy Now in 2024

CSL Limited (ASX:CSL)

CSL Limited offers a solid investment opportunity, particularly highlighted by its expected growth phase and positive endorsements from notable brokers like Citi, UBS, and Goldman Sachs. This biotech leader is poised for significant earnings growth, driven by increased plasma collection and the potential approval of new products.

With a focus on reducing capital expenditures and a promising pipeline of pre-clinical projects, CSL stands out as a stable and growth-oriented option in the healthcare sector.

ResMed (ASX:RMD)

ResMed Inc. is shaping up to be an enticing investment pick. With a strong recovery from its yearly low, it's catching the eye of top analysts who foresee a bright future. They're betting on a robust 27% upside, driven by solid growth across its products.

Despite some market jitters over new drugs, the experts are confident these concerns are overblown. This makes ResMed's current price a potential bargain. With key financial updates on the horizon, the company's shares seem undervalued, offering a golden opportunity for those looking to invest in the dynamic healthcare sector.

Telix Pharmaceuticals (ASX:TLX)

Telix Pharmaceuticals is an exciting investment choice in the biotech field, especially for its groundbreaking work in cancer treatments.

With a remarkable 165% jump from its 2022 low point, the company has made a significant leap from a pre-revenue stage to earning revenue, thanks to the successful launch of Illucix, their prostate cancer imaging product. Currently, after a slight dip in its share price, Telix presents an attractive buying opportunity.

Neuren Pharmaceuticals (ASX:NEU)

This company is making waves in the biotech sector, notably with its breakthrough Rett syndrome treatment, Daybue. This game-changer has not only brought substantial royalty income but also placed Neuren at the forefront of innovative medical solutions, increasing its market capitalization substiantially in the past year.

The company's dynamic approach doesn’t stop there; it’s developing exciting new treatments, like NNZ-2591 for Phelan-McDermid syndrome, targeting unmet medical needs. With analysts like Bell Potter predicting more growth, Neuren's blend of steady income from Daybue and potential future successes presents a compelling investment opportunity.

Avita Medical (ASX:AVH)


AVITA Medical is making waves in regenerative medicine, with its share price skyrocketing over 120% in 2023. The company’s recent quarterly report revealed a stellar 50% jump in revenue, signalling strong market traction. Analysts are lining up in support, with all giving a thumbs-up.

The buzz is building for its upcoming yearly results, where a hefty 40% rise in sales is anticipated and an increase in market cap. The cherry on top? The potential FDA nods for its innovative Recell Go product in May. With these exciting developments, AVITA Medical stands out as a highly promising pick in the healthcare investment arena.

Pros and Cons of Investing in Biotech Stocks ASX

The biotech sector is forecasted to grow at a compound annual rate of 8.7% until 2030. This growth is driven by continuous advancements in medical technology and an increasing global demand for innovative healthcare solutions.

In regions like China and other developing nations, government initiatives are promoting the growth of biotech. These initiatives aim to simplify the process of bringing new products to market, from streamlining regulatory pathways to standardizing clinical studies, thereby accelerating product approvals.

Investing in biotech requires thorough research to understand the potential and effectiveness of products. Companies that develop drugs addressing significant health issues or that offer cost-effective technological solutions tend to have a higher success rate. This focus on community needs and healthcare affordability is crucial for the success of biotech firms.

However, the biotech sector's complexity poses a challenge for investors without a medical or scientific background. It can be difficult to evaluate the potential of biotech products and their likelihood of success in the market, adding layers of uncertainty to investment decisions.

Retail investors often depend on financial analysts for insights into promising biotech shares. While a 'buy' rating from an investment house can increase stock prices, these gains are not always sustained, introducing an element of volatility and uncertainty.

The journey to market for biotech products, especially those targeting rare diseases, is fraught with challenges. Each step, from clinical trials to regulatory approvals, carries the risk of failure. If a drug fails to get approval or a company reports unfavourable trial results, share prices can plummet swiftly, highlighting the high-risk nature of biotech investments.

How to Choose the Right ASX Biotech Shares?

Selecting the perfect ASX biotech stock requires thorough research, a dose of patience, and a knack for spotting future winners. Start by diving deep into the company's research activities. Are they working on diverse and groundbreaking medical treatments? Check their history: how well do they maneuver through the maze of clinical trials and regulatory approvals? Stable finances are key, as these companies often burn through cash for research before making a dime.

Also, gauge the market's appetite for their innovations and the competition they face. Remember, biotech investing is not for the faint-hearted. It's a high-stakes game with long product development timelines and potential regulatory hurdles.

Success in this sector often comes from backing those innovators who are not just dreaming up futuristic medical solutions, but also possess the smarts to bring these dreams to life in the market.

Are ASX Biotech Stocks right for you?

Deciding whether ASX biotech stocks are right for you hinges on your investment profile and risk tolerance. These stocks offer the thrilling possibility of being part of groundbreaking medical advancements, potentially yielding substantial returns.

However, they're not without their risks - the long and uncertain road to product development and regulatory approvals can be daunting.

If you're the type who relishes the idea of investing in cutting-edge medical research with the potential for high rewards, and you're comfortable with the accompanying volatility and long-term commitment, then biotech stocks might be a fitting addition to your portfolio. But if stability and predictability are more your style, you might want to look elsewhere.

Frequently Asked Questions (FAQs)

ASX Biotech Stocks are shares of companies in the Australian biotechnology sector, engaged in medical, agricultural, or environmental technology using biological systems. These companies focus on innovative healthcare solutions, including drug development and genetic research.

Our Blogs on Biotech Stocks

Undervalued Australian growth shares

Undervalued Australian growth shares : Here are 4 of our favourites

January 9, 2024

Undervalued Australian growth shares are difficult to find, but they are not impossible. Stocks Down Under outlines how to look…

best asx stocks in august

Here are the 3 Best ASX stocks in August

August 16, 2023

In this article, we look at the Best ASX stocks in August. We’re half-way through reporting season and while not…

undervalued tech stocks

4 astonishingly undervalued tech stocks for growth-oriented investors to consider

May 29, 2023

The Tech Wreck has created opportunities for investors to buy undervalued Tech stocks. But some represent better opportunities than others.…

find undervalued stocks

How to find undervalued stocks? Here are 3 useful tools to help start your search

April 27, 2023

How can investors find undervalued stocks? It is a fine art, but it’s not impossible. In this article, we recap…

dusk group

Dusk Group smells >40% undervalued: Here’s why it may rebound

April 4, 2023

Dusk Group (ASX:DSK) purports to be Australia’s favourite home fragrance seller. Investors haven’t been sharing the love for it as…